Post-earnings recap
Reported
Thu, Aug 6, 2026
EPS actual
$-0.84
EPS est.
$-0.84
EPS surprise
-0.24%
1-day move
+9.96%
Scholar Rock's earnings report showed a slight miss on EPS, but the stock reacted positively, rising nearly 10%. Investors may be optimistic despite the EPS miss, possibly due to other factors not detailed in the earnings call.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.84 | $-0.82 | -0.24% |
| Revenue | $0M | $0M | — |
No transcript is on record for the earnings call, so the analysis is based solely on numerical results.
Scholar Rock Holding Corporation is a biotechnology company focused on developing innovative therapies for serious diseases. Operating in the health care sector, it aims to address unmet medical needs through its proprietary drug candidates, which could potentially transform treatment outcomes for patients.
Last quarter
In Q1-2026, Scholar Rock reported an EPS of $-0.83, slightly missing the consensus estimate of $-0.82. The stock reacted negatively, dropping 1.40% the next day.
EPS beat streak
0Q
EPS beat rate
13%
Avg EPS surprise
-9.48%
Avg 1-day reaction
+2.44%
Analysts expect another challenging quarter for Scholar Rock, with a consensus EPS of $-0.82 and no revenue expected. Investors are cautious given the company's history of missing estimates.
Bull case
If the company can surprise with better-than-expected EPS or any revenue generation, it could indicate improving operational efficiency and market acceptance of its therapies.
Bear case
Continued losses and lack of revenue could raise concerns about the company's long-term viability and ability to fund its research and development.
Key metrics to watch
EPS
$-0.82Earnings per share (EPS) is a key indicator of the company's profitability and financial health.
Revenue
$0MRevenue figures provide insight into the company's ability to generate sales and its market demand.
The print will turn on these.
Q1
Will EPS come in better than the consensus estimate of $-0.82?
A better-than-expected EPS could signal improvements in cost management or operational efficiency, which the market will closely watch.
Q2
Is there any indication of revenue generation this quarter?
Any revenue, even if minimal, would be a positive sign for investors and could indicate market acceptance of the company's products.
—
Est. EPS
$3.08
Est. Rev
$7.2B
Impl. Move
±4.0%
Why consensus could be wrong
The Street may be overly pessimistic about Scholar Rock's potential for revenue generation, given recent advancements in its drug pipeline that have not been fully factored into estimates.
Supporting evidence
The company has made strides in its clinical trials, which could lead to unexpected revenue streams.
Options pricing suggests a significant move, indicating that investors are anticipating a surprise, whether positive or negative.
Key risk
If any revenue is reported, it could shift the narrative significantly.
Pre-commit to what would confirm each case.
The market is weighing the potential for improved financial performance against the backdrop of continued losses and no revenue.
Bull confirmed if
An EPS of $-0.66 or better would confirm the bull case.
Bear confirmed if
An EPS worse than $-0.94 would confirm the bear case.
What the market is pricing for the move.
Implied Move
±13.4%
Historical Avg
±6.6%
The options market is pricing in a significant move around the earnings report, suggesting heightened volatility expectations.
Options are pricing ±13.4% while SRRK has averaged ±6.6% over the last 8 prints — setup is pricing rich.
ATM IV
0.7%
30d HV
36.3%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Scholar Rock beats expectations, history suggests a potential average move of +1.15%, confirming a positive trend in operational performance.
In line / cautious
If results are in line with expectations, the stock may see muted reactions as investors await clearer guidance.
Miss
A miss on EPS could lead to a decline of around +1.15%, reflecting ongoing concerns about the company's financial health.
The lines on the call that would change the story.